Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 393-406

  Ismail, Manal Fouad ^a   Elmeshad, Aliaa Nabil ^a   Salem, Neveen Abdel Hameed ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Alzheimer's disease; Gene expression; Liposomes; Rats; Rivastigmine

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BETA SECRETASE 1; C REACTIVE PROTEIN; HOMOCYSTEINE; INTERLEUKIN 1BETA; LIPOSOME; N(G),N(G) DIMETHYLARGININE; RIVASTIGMINE;

ACETYLCHOLINESTERASE GENE; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACE1 GENE; CONTROLLED STUDY; DETERIORATION; DOWN REGULATION; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; ENZYME ACTIVITY; GENE; GENE EXPRESSION REGULATION; HEATING; HYDRATION; IL1B GENE; MALE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SPATIAL MEMORY;

ALZHEIMER'S DISEASE; GENE EXPRESSION; LIPOSOMES; RATS; RIVASTIGMINE;

ACETYLCHOLINESTERASE; ALUMINUM COMPOUNDS; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; C-REACTIVE PROTEIN; CHLORIDES; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; LIPOSOMES; MALE; MAZE LEARNING; NANOPARTICLES; PARTICLE SIZE; PHENYLCARBAMATES; RATS; RATS, WISTAR;

EID: 84873053242     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S39232     Document Type: Article

References (76)

1. Mount C, Downton C. Alzheimer disease: progress or profit? Nat Med. 2006;12:780-784.
2. Sinha S, Lieberburg I. Cellular mechanisms of beta-amyloid protein production and secretion. Proc Natl Acad Sci U S A. 1999;96: 11049-11053.
3. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
4. Gonzalez-Scarano F, Baltuch. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci. 1999;22:219-240.
5. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e) inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000;20:1557-1564.
6. Gulya K, Rakonczay Z, Kása P. Cholinotoxic effects of aluminum in rat brain. J Neurochem. 1990;54:1020-1026.
7. Garcia T, Esparza JL, Nogués MB, Romeu M, Domingo JL, Gomez M. Oxidative stress status and RNA expression in hippocampus of an animal model of Alzheimer's disease after chronic exposure to aluminum. Hippocampus. 2010;20:218-225.
8. Cummings JL, Cole G. Alzheimer disease. JAMA. 2002;287: 2335-2338.
9. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387-403.
10. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med. 2007;4:e338.
11. Wang RH, Bejar C, Weinstock M. Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats. Neuropharmacology. 2000;39:497-506.
12. Bihaqi SW, Sharma M, Singh AP, Tiwari M. Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain. J Ethnopharmacol. 2009;124:409-415.
13. Camps P, Muñoz-Torrero D. Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem. 2002;2:11-25.
14. Novartis Pharmaceuticals. Exelon monograph. East Hanover (NJ): Novartis Pharmaceuticals; 2004.
15. Arumugam K, Subramanian GS, Mallayasamy SR, Averineni RK, Reddy MS, Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm. 2008;58:287-297.
16. Degim Z, Mutlu MB, Yilmaz S, Eşsiz D. Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). Pharmazie. 2010;65:32-40.
17. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010;76:189-199.
18. Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J Control Release. 2011;152:208-231.
19. Allen TM, McAllister L, Mausolf S, Gyorffy E. Liposome-cell interactions. A study of the interactions of liposomes containing entrapped anti-cancer drugs with the EMT6, S49 and AE1 (transport-deficient) cell lines. Biochim Biophys Acta. 1981;643:346-362.
20. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145-160.
21. Brasnjevic I, Steinbusch H, Schmitz C, Martinez-Martinez P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol. 2009;87:212-251.
22. Mutlu NB, Deǧim Z, Yilmaz Ş, Eşsiz D, Nacar A. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev Ind Pharm. 2011;37:775-789.
23. Vemuri S, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv. 1995;70: 95-111.
24. Mozafari MR, Reed CJ, Rostron C, Kocum C, Piskin E. Formation and characterisation of non-toxic anionic liposomes for delivery of therapeutic agents to the pulmonary airways. Cell Mol Biol Lett. 2002;7: 243-244.
25. Salem MA, El-Kosasy AM, El-Bardicy MG, Abd El-Rahman MK. Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product. Drug Test Anal. 2010;2:225-233.
26. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47-60.
27. den Blaauwen DH, Poppe WA, Tritschler W. Cholinesterase (EC 3.1.1.8) with butyrylthiocholine-iodide as substrate: references depending on age and sex with special reference to hormonal effects and pregnancy. J Clin Chem Clin Biochem. 1983;21:381-386.
28. Sovoboda P, Mossinger B. Catecholamines and brain microsomal Na, K-adenosinetriphosphatase I. Protection against lipoperoxidative damage. Biochem Pharmacol. 1981;30:427-432.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem. 1951;193:265-275.
30. Kikuchi H, Yamauchi H, Hirota S. A polyol dilution method for mass production of liposomes. J Liposome Res. 1994;4:71-91.
31. Cortesi R, Esposito E, Gambarin S, Telloli P, Menegatti E, Nastruzzi C. Preparation of liposomes by reverse-phase evaporation using alternative organic solvents. J Microencapsul. 1999;16:251-256.
32. Bar R. Phase toxicity in a water-solvent two-liquid phase microbial system. In: Laane C, Tramper J. Biocatalysis in Organic Media. In: Lilly MD, editor. Amsterdam, Netherlands: Elsevier Science; 1987:147-153.
33. Ivanov IT. Rapid method for comparing the cytotoxicity of organic solvents and their ability to destabilize proteins of the erythrocyte membrane. Pharmazie. 2001;56:808-809.
34. Dwivedi AM. Residual solvent analysis in pharmaceuticals. Pharm Tech Eur. 2002;14:42-46.
35. Mozafari MR, Reed CJ, Rostron C. Cytotoxicity evaluation of anionic nanoliposomes and nanolipoplexes prepared by the heating method without employing volatile solvents and detergents. Pharmazie. 2007;62:205-209.
36. Mozafari MR, Reed CJ, Rostron C, Kocum C, Piskin E. Construction of stable anionic liposome-plasmid particles using the heating method: a preliminary investigation. Cell Mol Biol Lett. 2002;7:923-927.
37. Mozafari MR. Nanoliposomes: preparation and analysis. In: Weissig V, editor. Liposomes: Methods and Protocols. Volume 1: Pharmaceutical Nanocarriers. New York: Springer; 2010:48.
38. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res. 2000;17:521-525.
39. Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr Drug Deliv. 2005;2:429-441.
40. New RRC. Preparation of liposomes. In: New RRC, editor. Liposomes: A Practical Approach. New York: Oxford University Press; 1990: 36-90.
41. Reineccius G. Liposomes for controlled release in the food industry. In: Risch S, Reineccius G, editors. Encapsulation and Controlled Release of Food Ingredients. Washington: American Chemical Society; 1995:113-131.
42. Thompson AK, Mozafari MR, Singh H. The properties of liposomes produced from milk fat globule membrane material using different techniques. Lait. 2007;87:349-360.
43. Nagayasu A, Uchiyama K, Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev. 1999;40:75-87.
44. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47:3-19.
45. Bayomi MA, Al-Suwaych SA, El-Helw AM, Mesnad AF. Preparation of casein chitosan microspheres containing diltiazem hydrochloride by an aqueous coacervation technique. Pharm Acta Helv. 1998;7: 187-192.
46. McLachlan DR, Bergeron C, Smith JE, Boomer D, Rifat SL. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology. 1996;46:401-405.
47. Campbell A, Becaria A, Lahiri DK, Sharman K, Bondy SC. Chronic exposure to aluminium in drinking water increases inflammatory parameters selectively in the brain. J Neurosci Res. 2004;75:565-572.
48. Rabe A, Lee MH, Shek J, Wisniewski HM. Learning deficit in immature rabbits with aluminium-induced neurofibrillary changes. Exp Neurol. 1982;76:441-446.
49. Canales JJ, Corbalán R, Montoliu C, et al. Aluminium impairs the glutamate-nitric oxide-cGMP pathway in cultured neurons and in rat brain in vivo: molecular mechanisms and implications for neuropathology. J Inorg Biochem. 2001;87:63-69.
50. Zaciragic A, Lepara O, Valjevac A, et al. Elevated serum C-reactive protein concentration in Bosnian patients with probable Alzheimer's disease. J Alzheimers Dis. 2007;12:151-156.
51. Ho YS, Yu MS, Yang XF, So KF, Yuen WH, Chang RC. Neuroprotective effects of polysaccharides from wolfberry, the fruits of Lycium barbarum, against homocysteine induced toxicity in rat cortical neurons. J Alzheimers Dis. 2010;19:813-827.
52. Stolp HB, Dziegielewska KM. Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol. 2009;35:132-146.
53. Strang F, Scheichl A, Chen YC, et al. Amyloid plaques dissociate pentameric to monomeric C-reactive protein:A novel pathomechanism driving cortical inflammation in Alzheimer's disease? Brain Pathol. 2012;22:337-346.
54. Kamath AF, Chauhan AK, Kisucka J, et al. Elevated levels of Hcy compromise blood brain barrier integrity in mice. Blood. 2006;107: 591-593
55. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and Hcy impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of AD. J Neurosci. 2002;22:1752-1762.
56. Zhang CE, Wei W, Liu YH, Peng JH, Tian Q, Handy DE. Hyperhomocysteinemia increases β amyloid by enhancing expression of γ-secretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol. 2009;174:1481-1491.
57. Selley ML. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons. J Neurosci Res. 2004;77:90-93.
58. Swegert CV, Dave KR, Katyare SS. Effect of aluminium induced Alzheimer like condition on oxidative energy metabolism in rat liver, brain and heart mitochondria. Mech Ageing Dev. 1999;112:27-42.
59. Silva VS, Nunes MA, Cordeiro JM, et al. Comparative effects of aluminium and ouabain on synaptosomal choline uptake, acetylcholine release and (Na+/K+) ATPase. Toxicology. 2007;236:158-177.
60. Castorina A, Tiralongo A, Giunta S, Carnazza ML, Scapagnini G, D'Agata V. Early effects of aluminum chloride on beta-secretase mRNA expression in a neuronal model of beta-amyloid toxicity. Cell Biol Toxicol. 2010;26:367-377.
61. Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem. 2002;277:45518-45528.
62. Chen L, Na R, Gu M, Richardson A, Ran Q. Lipid peroxidation upregulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease. J Neurochem. 2008;107:197-207.
63. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro and anti-inflammatory cytokines in dementias. Brain Res Bull. 2003;61:255-260.
64. van Rensburg SJ, Daniels WM, Potocnik FC, van Zyl JM, Taljaard JJ, Emsley RA. A new model for the pathophysiology of Alzheimer's disease. Aluminum toxicity is exacerbated by hydrogen peroxide and attenuated by an amyloid protein fragment and melatonin. S Afr Med J. 1997;87:1111-1115.
65. Lukiw WJ, Percy ME. Nanomolar aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem. 2005;99:1895-1898.
66. Taylor JM, Crack PJ. Impact of oxidative stress on neuronal survival. Clin Exp Pharmacol Physiol. 2004;31:397-406.
67. Li Y, Liu L, Kang J, et al. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci. 2000;20:149-155.
68. Pavlov VA, Tracey KJ. Controlling inflammation: the cholinergic antiinflammatory pathway. Biochem Soc Trans. 2006;34:1037-1040.
69. Gambi F, Reale M, Iarlori C, et al. Alzheimer patients treated with an AChE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. J Clin Psychopharmacol. 2004;24:314-321.
70. Nizri E, Irony-Tur-Sinai M, Faranesh N, et al. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol. 2008;203:12-22.
71. Pollak Y, Gilboa A, Menachem O, Ben-Hur T, Soreq H, Yirmiya R. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1 β production. Ann Neurol. 2005;57:741-745.
72. Stefanova E, Wall A, Almkvist O, et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm. 2006;113:205-218.
73. Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-b-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. 1996;16:881-891.
74. Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Ab and increases sAPPa levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One. 2011;6:e21954
75. Hartlage-Rübsamen M, Zeitschel U, Apelt J, et al. Astrocytic expression of the Alzheimer's disease beta secretase (BACE1) is stimulusdependent. Glia. 2003;41:169-179.
76. Kumar P, Kumar A. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations. Eur J Pharmacol. 2009;615:91-101.